Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders-Reference-Cited by-同舟云学术

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Published:2023-08-30 Issue:9 Volume:11 Page:2424
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Bagnasco Diego¹²^ORCID,Nicola Stefania³^ORCID,Testino Elisa¹²,Brussino Luisa³^ORCID,Pini Laura⁴^ORCID,Caminati Marco⁵^ORCID,Piccardo Federica²,Canevari Rikki Frank⁶^ORCID,Melissari Laura¹²,Ioppi Alessandro⁶^ORCID,Guastini Luca⁶,Lombardi Carlo⁷^ORCID,Milanese Manlio⁸,Losa Francesca⁹^ORCID,Robbiano Michela¹²,De Ferrari Laura¹²,Riccio Anna Maria¹²,Guida Giuseppe¹⁰^ORCID,Bonavia Marco¹¹,Fini Donatella¹²,Balbi Francesco¹³,Caruso Cristiano¹⁴,Paggiaro Pierluigi¹⁵,Blasi Francesco¹⁶¹⁷^ORCID,Heffler Enrico¹⁸¹⁹^ORCID,Paoletti Giovanni¹⁸¹⁹^ORCID,Canonica Giorgio Walter¹⁸¹⁹,Senna Gianenrico⁵^ORCID,Passalacqua Giovanni¹²,

Affiliation:

1. Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy

2. Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy

3. SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy

4. Respiratory Medicine Unit, ASST—“Spedali Civili” of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy

5. Department of Medicine, University of Verona, 37134 Verona, Italy

6. ENT Department, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy

7. Departmental Unit of Allergology, Immunology & Pulmonary Diseases, Fondazione Poliambulanza, 25124 Brescia, Italy

8. Department of Respiratory Diseases, S. Corona Hospital, ASL2, 17027 Pietra Ligure, Italy

9. UO Allergology and Clinical Immunology, ASST Mantova, 46100 Mantova, Italy

10. Department of Clinical and Biological Science, University of Torino, 10043 Orbassano, Italy

11. Department of Rehabilitation Pulmonology, Hospital Ge-Arenzano, ASL3, 16149 Genoa, Italy

12. Department of Pneumologiy, Hospital Sarzana (SP), 19125 La Spezia, Italy

13. Department of Pneumologiy, Hospital Imperia, 18100 Imperia, Italy

14. Department of di Medical and Surgical Science, Fondation Universitary Policlinic A. Gemelli IRCCS, University Cattolica Sacro Cuore, 20123 Rome, Italy

15. Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, 56126 Pisa, Italy

16. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy

17. Respiratory Unit and Adult Cystic Fibrosis Center, Internal Medicine Department, Fondation IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy

18. Unit of Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Clinical and Research Hospital, 20089 Rozzano, Italy

19. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy

Abstract

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (−84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting.

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Link

https://www.mdpi.com/2227-9059/11/9/2424/pdf

Reference46 articles.

1. Chiu, C.-J., and Huang, M.-T. (2021). Asthma in the Precision Medicine Era: Biologics and Probiotics. Int. J. Mol. Sci., 22.

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur. Respir. J.,2013

3. Kyriakopoulos, C., Gogali, A., Bartziokas, K., and Kostikas, K. (2021). Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res., 7.

4. Innate Lymphocytes -ILC2—Might Be the Drivers of T2-High Nonatopic Asthma in Children;Bonato;Eur. Respir. J.,2021

5. Type 2 Inflammation in Asthma-Present in Most, Absent in Many;Fahy;Nat. Rev. Immunol.,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SANI clinical remission definition: a useful tool in severe asthma management;Journal of Asthma;2024-07-23

2. Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series;Drugs in Context;2024-07-22

3. Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab;Biomedicines;2024-04-26

4. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study;2024-03-15

5. Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy;Pharmaceutics;2023-09-21